Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI) is a Healthcare company (Medical - Devices) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Lumexa Imaging Holdings, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $14.63, Lumexa Imaging Holdings, Inc. Common Stock trades at 1.3x sales and 2.2x book value, with an EV/EBITDA of 21.1. Over the last twelve months it generated about $1.1B of revenue and a net loss of $25M. It runs a gross margin of 12.3%, an operating margin of 0.6% and a net margin of -1.6%. It shows return on equity of -2.8%, return on invested capital of 0.4% and a free cash flow yield of 3.9%. On the balance sheet: a debt-to-equity ratio of 1.54 and a current ratio of 1.52. Over the past 52 weeks the share price ranged from $6.45 to $19.45, with a beta of 0.99.
Lumexa Imaging Holdings, Inc. Common Stock does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 1 Strong Buy and 1 Buy, for a Strong Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography. The company was founded in 2018 and its primary base of operations is in Raleigh, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Lumexa Imaging Holdings, Inc. Common Stock (LMRI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 75.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 46.4% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 75.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.06% / 33% · Receivables / Mkt Cap (36m) 15.5% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 75.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.06% / 33.33% · Receivables / Mkt Cap (24m) 15.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 46.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.76% / 33.33% · Receivables / Avg Assets (4Q) 9.08% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 45.7% / 33.33% · (Cash+ST Inv) / Total Assets 4.91% / 33.33% · (Cash+Recv) / Total Assets 14.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Lumexa Imaging Holdings, Inc. Common Stock (LMRI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Lumexa Imaging Holdings, Inc. Common Stock is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Lumexa Imaging Holdings, Inc. Common Stock reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.